Company intelligence / Profile preview

Zhittya Genesis Medicine

Las Vegas, Nevada, United States

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Completed first-in-human research study for Parkinson's disease treatment using intranasal FGF-1 delivery. Recent fMRI study showed 21.2% boost in brain blood flow and 54% improvement in motor skills in Parkinson's patients after six months of treatment.

Therapeutic areas: EndocrinologyCardiovascularNeurology
Modalities: Biological drug (FGF-1)
Industry: Biotech

Drug pipeline

1 asset

fgf-1

Phase 2

Indications: Coronary artery disease, Parkinson's disease, ALS

Beyond the preview

Go deeper on Zhittya Genesis Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhittya Genesis Medicine.

Explore the full profile